Larimar Therapeutics (Larimar Therapeutics) Cash-to-Debt : 15.65 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Larimar Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 15.65.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Larimar Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Larimar Therapeutics's Cash-to-Debt or its related term are showing as below:

LRMR' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.4 Med: 14.22 Max: 21.9
Current: 15.65

During the past 5 years, Larimar Therapeutics's highest Cash to Debt Ratio was 21.90. The lowest was 10.40. And the median was 14.22.

LRMR's Cash-to-Debt is ranked better than
61.97% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs LRMR: 15.65

Larimar Therapeutics Cash-to-Debt Historical Data

The historical data trend for Larimar Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Larimar Therapeutics Cash-to-Debt Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

10.40

14.22

11.68

21.90

15.65

Larimar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial														21.90	21.26	20.52	17.74	15.65

Competitive Comparison of Larimar Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Larimar Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's Cash-to-Debt falls into.

Larimar Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Larimar Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	86.79	/	(0.837	+	4.709)
	=	15.65

Larimar Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	86.79	/	(0.837	+	4.709)
	=	15.65

Larimar Therapeutics (NAS:LRMR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Larimar Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics (Larimar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZA71:Germany

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Executives

Gopi Shankar	officer: Chief Development Officer	C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Russell Clayton	officer: Chief Medical Officer	2600 KELLY RD, WARRINGTON PA 18976
Carole Ben-maimon	director, officer: President and CEO	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Michael Celano	officer: Chief Financial Officer	220 EAST FIRST STREET, BETHLEHEM PA 18015
Joseph Truitt	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Thomas Edward Hamilton	director	211 STUYVESANT AVE, RYE NY 10580
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Jonathan S Leff	director	C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Hif, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Chondrial Therapeutics Holdings, Llc	10 percent owner	150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Healthcare Innovations Fund, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iii, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017